| Dr Glenn J Hanna, MD | |
|
450 Brookline Ave, Boston, MA 02215-5418 | |
| (617) 632-3779 | |
| (617) 632-5822 |
| Full Name | Dr Glenn J Hanna |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 14 Years |
| Location | 450 Brookline Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750602983 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 253236 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Brigham And Women's Hospital | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dana-farber Cancer Institute, Inc. | 9133038904 | 538 |
News Archive
In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.
Research from the USA suggests that while urodynamic testing is well-tolerated by women on the whole, patients who are younger, or have anxiety or depression may have more negative experiences of the procedure than other patients.
A study published in European Journal of Heart Failure reported that the risk of heart failure was more than twelve times higher in elderly vitamin D deficient participants than those with an adequate level.
Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).
The U.S. Green Building Council has awarded the Orthopedic Building at Rush University Medical Center Gold Leadership in Energy and Environmental Design (LEED) certification. LEED is an internationally recognized green building certification system and the nationally accepted benchmark for the design, construction and operation of high performance green buildings.
› Verified 1 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194765438 PECOS PAC ID: 4486567104 Enrollment ID: O20031204000918 |
News Archive
In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.
Research from the USA suggests that while urodynamic testing is well-tolerated by women on the whole, patients who are younger, or have anxiety or depression may have more negative experiences of the procedure than other patients.
A study published in European Journal of Heart Failure reported that the risk of heart failure was more than twelve times higher in elderly vitamin D deficient participants than those with an adequate level.
Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).
The U.S. Green Building Council has awarded the Orthopedic Building at Rush University Medical Center Gold Leadership in Energy and Environmental Design (LEED) certification. LEED is an internationally recognized green building certification system and the nationally accepted benchmark for the design, construction and operation of high performance green buildings.
› Verified 1 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346433257 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000142 |
News Archive
In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.
Research from the USA suggests that while urodynamic testing is well-tolerated by women on the whole, patients who are younger, or have anxiety or depression may have more negative experiences of the procedure than other patients.
A study published in European Journal of Heart Failure reported that the risk of heart failure was more than twelve times higher in elderly vitamin D deficient participants than those with an adequate level.
Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).
The U.S. Green Building Council has awarded the Orthopedic Building at Rush University Medical Center Gold Leadership in Energy and Environmental Design (LEED) certification. LEED is an internationally recognized green building certification system and the nationally accepted benchmark for the design, construction and operation of high performance green buildings.
› Verified 1 days ago
| Entity Name | Dana-farber Cancer Institute, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851333686 PECOS PAC ID: 9133038904 Enrollment ID: O20040223000228 |
News Archive
In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.
Research from the USA suggests that while urodynamic testing is well-tolerated by women on the whole, patients who are younger, or have anxiety or depression may have more negative experiences of the procedure than other patients.
A study published in European Journal of Heart Failure reported that the risk of heart failure was more than twelve times higher in elderly vitamin D deficient participants than those with an adequate level.
Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).
The U.S. Green Building Council has awarded the Orthopedic Building at Rush University Medical Center Gold Leadership in Energy and Environmental Design (LEED) certification. LEED is an internationally recognized green building certification system and the nationally accepted benchmark for the design, construction and operation of high performance green buildings.
› Verified 1 days ago
| Entity Name | Beth Israel Deaconess Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548202641 PECOS PAC ID: 8123936119 Enrollment ID: O20041001000827 |
News Archive
In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.
Research from the USA suggests that while urodynamic testing is well-tolerated by women on the whole, patients who are younger, or have anxiety or depression may have more negative experiences of the procedure than other patients.
A study published in European Journal of Heart Failure reported that the risk of heart failure was more than twelve times higher in elderly vitamin D deficient participants than those with an adequate level.
Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).
The U.S. Green Building Council has awarded the Orthopedic Building at Rush University Medical Center Gold Leadership in Energy and Environmental Design (LEED) certification. LEED is an internationally recognized green building certification system and the nationally accepted benchmark for the design, construction and operation of high performance green buildings.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Glenn J Hanna, MD 450 Brookline Ave, Boston, MA 02215-5418 Ph: (617) 632-3779 | Dr Glenn J Hanna, MD 450 Brookline Ave, Boston, MA 02215-5418 Ph: (617) 632-3779 |
News Archive
In the battle against cancer and other diseases, precise analysis of specific proteins can point the way toward targeted treatments. Scientists at theTechnische Universitaet Muenchen, together with Fujitsu Laboratories of Japan, have developed a novel biosensor chip that not only recognizes proteins that are characteristic for specific diseases, but also can show if these proteins are changed through the influence of disease or drugs.
Research from the USA suggests that while urodynamic testing is well-tolerated by women on the whole, patients who are younger, or have anxiety or depression may have more negative experiences of the procedure than other patients.
A study published in European Journal of Heart Failure reported that the risk of heart failure was more than twelve times higher in elderly vitamin D deficient participants than those with an adequate level.
Neovacs, a biotechnology company developing proprietary immunotherapies for autoimmune and chronic diseases, today announced the initiation of a Phase IIa clinical study of its TNFα Kinoid immunotherapy in rheumatoid arthritis patients who have ceased to respond to an anti-TNFα monoclonal antibody and who test positive for anti-drug antibodies (ADAs).
The U.S. Green Building Council has awarded the Orthopedic Building at Rush University Medical Center Gold Leadership in Energy and Environmental Design (LEED) certification. LEED is an internationally recognized green building certification system and the nationally accepted benchmark for the design, construction and operation of high performance green buildings.
› Verified 1 days ago
Kaitlyn My-tu Lam, MBBS Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |